Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer

NCT06462105 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection

Sponsor

Zhou Chengzhi

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]